腫瘍学市場におけるAI – 2030年までの世界予測

Report Overview

The global AI in Oncology market is projected to reach USD 11.52 billion by 2030 from USD 2.45 billion in 2024, at a CAGR of 29.4% from 2024 to 2030.

世界の腫瘍学市場におけるAIは、2024年から 2030年までの CAGR 29.4% で、2024年の 24 億 5,000 万米ドルから 2030年までに 115 億 2,000 万米ドルに達すると予測されています。

The market’s growth is fuelled by the growing demand for cost-effective cancer treatments & solutions, streamlining of the drug discovery process, rapid digitization of healthcare records and patient data, the growing volume of cancer cases, and regulatory compliance requirements.

市場の成長は、費用対効果の高いがん治療とソリューションに対する需要の高まり、創薬プロセスの合理化、医療記録と患者データの急速なデジタル化、がん症例の増加、規制遵守要件によって促進されています。

In March 2024, the journal published by the American Cancer Society stated the following key points:

• More than 80% of AI devices that are FDA-approved are used in cancer detection & diagnosis. These devices have applications in the following: pathology (19.7%), radiology (54.9), and radiation oncology (8.5%).
• AI aided in decreasing the workload of radiologists in breast cancer screening by 30% and in comparison to healthcare professionals, AI maintained more accuracy.
• AI combined with human evaluations improved cancer detection rates by 8% in various studies.
• Precision medicine tools powered by AI contributed to the 33% decline in cancer mortality rates over the past 32 years by enabling better diagnoses, tailored treatments, and optimized clinical decision-making.

However, integration with existing healthcare systems, data privacy, and security constraints pose a significant challenge within this market.

“Machine learning held the largest share in technology type in the AI in oncology market in 2023.”

The AI in oncology market is segmented based on technology into machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, and image analysis (including optical character recognition). The machine learning segment held the largest market share in 2023. Further, the machine learning segment includes deep learning (including convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies. Among these, deep learning is the largest segment owing to its capability to analyze and process vast and complex datasets including medical images with improved efficiency. Within deep learning technologies such as CNNs are effective for image-based cancer detection, while RNNs and GANs are used to improve the temporal pattern analysis and data synthesis. Moreover, deep learning’s scalability, adaptability and precision in analyzing and identifying the subtle patterns in cancer helped in improving the diagnosis, risk predictions and treatment optimization.

“By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.”

By player type, the AI in oncology market is divided into niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers. The integrated suite/platform providers segment accounts for the largest and is projected to be the fastest-growing segment over the forecast year. “By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.” The growth is attributed to the fact that these providers offer comprehensive end-to-end solutions to streamline workflows across all treatment sectors of cancer such as detection, diagnosis, monitoring, and treatment planning. Such platforms help to integrate technologies including NLP, computer vision, and machine learning resulting in better clinical decision-making and offering seamless data interoperability.

Moreover, integrated suite/platform helps in decreasing the need for multiple vendors as they are unified systems due to their scalability and flexibility which results in cost effective solution. This holistic approach drives adoption and fuels rapid growth.

“Asia Pacific is estimated to register the highest CAGR over the forecast period.”

The AI in Oncology market is segmented mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The AI in oncology market in Asia Pacific is projected to register at the highest CAGR rate during the forecast period. The growth of this region is due to the development of healthcare infrastructure, and government initiatives to modernize and digitalize the healthcare industry particularly due to rising cancer cases, growth in minimally invasive cancer treatments, and to increase in the survival rate of cancer patients. Countries such as Japan, China, and India are focusing on developing cost-effective solutions in cancer care emphasizing the importance of AI-driven data management to handle sensitive patient information and ensure compliance with regulatory mandates for healthcare data standardization. Various key players and startups in the countries are promoting AI use in cancer such as Niramai, a Bangalore-based health tech startup, developed Thermalytix, an AI-driven breast cancer screening solution. The technology uses non-invasive, radiation-free thermal imaging and machine learning algorithms to detect breast cancer at an earlier stage compared to traditional methods. The solution is designed for all ages and ensures privacy, portability, and high accuracy. It is available in over 30 cities across 200+ hospitals in India and is expanding globally to different countries, thereby, transforming preventive cancer care.

Breakdown of supply-side primary interviews by company type, designation, and region:

• By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%)
• By Designation: Directors (35%), Managers (40%), and Others (25%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%)

List of Companies Profiled in the Report

o               Certara USA. (US)

o               Siemens Healthineers (Germany)

o               GE Healthcare (US)

o               ConcertAI (US)

o               Medtronic (Ireland)

o               F. Hoffmann-La Roche Ltd (Switzerland)

o               Oracle(US)

o               NVIDIA Corporation(US)

o               Koninklijke Philips N.V. (Netherlands)

o               PathAI, Inc. (US)

o               CureMetrix, Inc. (US)

o               Mindpeak GmbH (Germany)

o               Paige AI, Inc. (US)

o               Predictive Oncology (US)

o               Exscientia (UK)

o               Insilico Medicine (US)

o               Iktos (Paris)

o               Tempus (US)

o               Azra AI (US)

o               CureMatch, Inc. (US)

o               OncoLens (US)

o               Triomics (US)

o               Clinakos. (US)

o               Perthera, Inc (US)

o               Cellworks Group, Inc. (US)

o               biomy, Inc. (Japan)

Research Coverage

This research report categorizes the AI in oncology market by player type [niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers], by application [drug discovery {target identification & validation, lead identification & optimization, de novo drug design}, drug development {preclinical testing, predictive modeling for human trials, clinical trial optimization, adaptive trial design & monitoring}, diagnosis & early detection {imaging & radiology (mammography, computed tomography, magnetic resonance imaging (MRI), nuclear imaging (PET & SPECT), X-ray imaging, ultrasound, others), digital pathology & histopathology, liquid biopsy & biomarker detection, genetic risk prediction}, treatment planning & personalization {personalized treatment planning (precision medicine & genomic analysis, radiomics and radiogenomics, predictive models for treatment response, treatment recommendation systems), radiation therapy, chemotherapy, immunotherapy, targeted therapy (combination & dose optimization, AI-guided drug delivery), surgical planning & assistance (preoperative imaging and 3D modeling, intraoperative guidance and robotics, postoperative analysis & recovery)}, patient engagement & remote monitoring {symptom management & virtual assistance, remote patient monitoring, patient education & empowerment}, post-treatment surveillance & survivorship care {recurrence monitoring, long-term outcome prediction, mental health & support systems}, data management & analytics, other applications, by cancer type (solid tumors [including breast cancer lung cancer, prostate cancer, colorectal cancer, brain tumors, and other tumors], hematologic malignancies (including leukemia, lymphoma, multiple myeloma, other hematologic malignancies), by technology [machine learning {deep learning (convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies}, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition)], by deployment [on-premises model, cloud-based model, and hybrid model], by end user [healthcare providers {hospitals & clinics, specialty centers, laboratories & diagnostic centers, others}, pharmaceutical & biotechnology companies, medical device/equipment companies, academic & research institutions, government & regulatory agencies, healthcare payers, and others}, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in oncology market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in oncology market. Competitive analysis of upcoming startups in the AI in oncology market ecosystem is covered in this report.

Reasons to Buy the Report

The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (supportive regulations, growing necessity to reduce healthcare costs, reduction in costs and improved operational efficiency with AI in oncology platforms, rising demand for streamlined clinical trials, technological advancements in AI algorithms, rising cancer prevalence globally), restraints (ensuring data security is a major concern for both patients and users, elevated costs associated with adoption of AI, resistance to adoption), opportunities (focus on personalized treatment plans, collaborative efforts, AI-driven drug discovery), and challenges (limited availability of datasets, interoperability issues) influencing the growth of the AI in oncology market
• Solution Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in oncology market
• Market Development: Comprehensive information about lucrative markets – the report analyses the AI in oncology market across varied regions.
• Market Diversification: Exhaustive information about new solutions, untapped geographies, recent developments, and investments in the AI in oncology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US), CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), Exscientia (UK), and Insilico Medicine (US), among others in AI in oncology market.

Table of Contents

1               INTRODUCTION              46

1.1           STUDY OBJECTIVES       46

1.2           MARKET DEFINITION   46

1.3           STUDY SCOPE   47

1.3.1        MARKET SEGMENTATION AND GEOGRAPHIC SPREAD                 47

1.3.2        INCLUSIONS AND EXCLUSIONS 48

1.3.3        YEARS CONSIDERED      51

1.4           CURRENCY CONSIDERED            51

1.5           STAKEHOLDERS               52

2               RESEARCH METHODOLOGY       53

2.1           RESEARCH DATA              53

2.1.1        SECONDARY DATA          54

2.1.1.1    Key data from secondary sources       55

2.1.2        PRIMARY DATA 55

2.1.2.1    Primary sources    56

2.1.2.1.1 Key data from primary sources           57

2.1.2.1.2 Key industry insights           58

2.1.2.2    Breakdown of primary interviews      58

2.2           MARKET ESTIMATION METHODOLOGY               59

2.3           MARKET SIZE ESTIMATION         60

2.4           MARKET BREAKDOWN AND DATA TRIANGULATION                 68

2.5           RESEARCH ASSUMPTIONS           69

2.5.1        MARKET SIZING ASSUMPTIONS                69

2.5.2        OVERALL STUDY ASSUMPTIONS              69

2.6           RISK ASSESSMENT           70

2.7           RESEARCH LIMITATIONS             70

2.7.1        METHODOLOGY-RELATED LIMITATIONS           70

2.7.2        SCOPE-RELATED LIMITATIONS                 70

3               EXECUTIVE SUMMARY  71

4               PREMIUM INSIGHTS       76

4.1           ATTRACTIVE OPPORTUNITIES FOR PLAYERS AI IN ONCOLOGY MARKET     76

4.2           AI IN ONCOLOGY MARKET, BY REGION 77

4.3           NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL AND COUNTRY 77

4.4           AI IN ONCOLOGY MARKET, BY COUNTRY             78

4.5           AI IN ONCOLOGY MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS    78

5               MARKET OVERVIEW       79

5.1           INTRODUCTION              79

5.2           MARKET DYNAMICS       79

5.2.1        DRIVERS               80

5.2.1.1    Increasing incidence of cancer disease              80

5.2.1.2    Growing need for early detection and diagnosis              80

5.2.1.3    Advancements in precision cancer treatment  81

5.2.1.4    Support from regulatory authorities  81

5.2.1.5    Increasing investments and funding 82

5.2.2        RESTRAINTS      83

5.2.2.1    High initial costs  83

5.2.2.2    Data integrity and algorithm validation            83

5.2.2.3    Integration with existing systems       83

5.2.3        OPPORTUNITIES              84

5.2.3.1    Radiomics and imaging analysis         84

5.2.3.2    Clinical trial optimization   86

5.2.3.3    Personalized treatment plans             86

5.2.3.4    Integration of multi-omics data          87

5.2.4        CHALLENGES    87

5.2.4.1    Limited availability of datasets           87

5.2.4.2    Data privacy and security    88

5.3           ECOSYSTEM ANALYSIS  89

5.4           CASE STUDY ANALYSIS 91

5.4.1        SIEMENS HEALTHINEERS IMPLEMENTED SYNGO.VIA RT IMAGE SUITE POWERED BY NVIDIA GPU-BASED SHERLOCK AI SUPERCOMPUTER     91

5.4.2        AI IN ONCOLOGY FOR PERSONALIZED TREATMENT PLANNING          91

5.4.3        PERSONALIZED OUTREACH FOR ONCOLOGISTS WITH TAKEDA’S AI SOLUTION               92

5.5           VALUE CHAIN ANALYSIS               93

5.6           PORTER’S FIVE FORCES ANALYSIS            95

5.6.1        BARGAINING POWER OF SUPPLIERS       96

5.6.2        BARGAINING POWER OF BUYERS             96

5.6.3        THREAT OF SUBSTITUTES          96

5.6.4        THREAT OF NEW ENTRANTS      97

5.6.5        INTENSITY OF COMPETITIVE RIVALRY 97

5.7           REGULATORY LANDSCAPE         97

5.7.1        NORTH AMERICA             97

5.7.2        EUROPE               98

5.7.3        ASIA PACIFIC     99

5.7.4        MIDDLE EAST & AFRICA                100

5.7.5        LATIN AMERICA                100

5.7.6        REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             100

5.8           PATENT ANALYSIS          103

5.8.1        PATENT PUBLICATION TRENDS FOR AI IN ONCOLOGY                 103

5.8.2        JURISDICTION ANALYSIS              104

5.8.3        MAJOR PATENTS IN AI IN ONCOLOGY MARKET 105

5.9           TECHNOLOGY ANALYSIS             106

5.9.1        KEY TECHNOLOGIES     106

5.9.1.1    Machine learning 106

5.9.1.2    Natural language processing               106

5.9.1.3    Computer vision   106

5.9.2        COMPLEMENTARY TECHNOLOGIES       107

5.9.2.1    High-performance computing            107

5.9.2.2    Next-generation sequencing               107

5.9.2.3    Digital twins          107

5.9.2.4    Real-world evidence/real-world data                 107

5.9.3        ADJACENT TECHNOLOGIES       107

5.9.3.1    Cloud computing  107

5.9.3.2    Theranostics          108

5.9.3.3    Augmented and virtual reality            108

5.10         INDUSTRY TRENDS         108

5.10.1      SHIFT TOWARD PERSONALIZED ONCOLOGY     108

5.10.2      EXPANSION OF AI-BASED CLINICAL TRIALS        108

5.11         PRICING ANALYSIS          109

5.11.1      INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE,

BY DEPLOYMENT MODEL            109

5.11.2      AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS,

BY REGION (2023)             109

5.12         KEY CONFERENCES AND EVENTS, 2025  110

5.13         KEY STAKEHOLDERS AND BUYING CRITERIA     111

5.13.1      KEY STAKEHOLDERS     111

5.13.2      BUYING CRITERIA           112

5.14         TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS            113

5.15         END USER ANALYSIS      113

5.15.1      UNMET NEEDS 113

5.15.2      END USER EXPECTATIONS          114

5.16         INVESTMENT AND FUNDING SCENARIO               114

5.17         IMPACT OF GENERATIVE AI ON AI IN ONCOLOGY MARKET               115

5.17.1      KEY USE CASES 116

5.17.2      CASE STUDIES OF GENERATIVE AI IMPLEMENTATION                 116

5.17.2.1  Case Study 1: Accelerated drug discovery with Generative AI and streamlined workflows         116

5.17.3      IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS   117

5.17.3.1  Pharmaceutical research and development market         117

5.17.3.2  Radiology and medical imaging market             117

5.17.3.3  Healthcare delivery systems market  118

5.17.4      USER READINESS AND IMPACT ASSESSMENT     118

5.17.4.1  User readiness       118

5.17.4.1.1                Use A: Healthcare providers               118

5.17.4.1.2                User B: Pharmaceutical & biotechnology companies                 118

5.17.4.2  Impact assessment                118

5.17.4.2.1                User A: Healthcare providers              118

5.17.4.2.2                User B: Pharmaceutical & biotechnology companies                 119

6               AI IN ONCOLOGY MARKET, BY TECHNOLOGY   120

6.1           INTRODUCTION              121

6.2           MACHINE LEARNING     121

6.2.1        DEEP LEARNING               124

6.2.1.1    Need to streamline clinical workflows, reduce delays, and improve patient outcomes to drive market       124

6.2.1.2    Convolutional neural networks           125

6.2.1.3    Recurrent neural networks 126

6.2.1.4    Generative adversarial networks        126

6.2.1.5    Graph neural networks        126

6.2.1.6    Others    126

6.2.2        SUPERVISED LEARNING                127

6.2.2.1    Surge in demand for accurate predictions and tailored treatments to drive market      127

6.2.3        REINFORCEMENT LEARNING     128

6.2.3.1    Extensive use in drug discovery to drive market              128

6.2.4        UNSUPERVISED LEARNING         129

6.2.4.1    Ability to perform complex tasks and uncover potential drug candidates to drive market  129

6.2.5        OTHER MACHINE LEARNING TECHNOLOGIES  130

6.3           NATURAL LANGUAGE PROCESSING       131

6.3.1        EMERGING DEVELOPMENTS IN ONCOLOGY CARE TO DRIVE MARKET 131

6.4           CONTEXT-AWARE PROCESSING AND COMPUTING                 132

6.4.1        ABILITY TO OPTIMIZE CLINICAL WORKFLOWS TO DRIVE MARKET 132

6.5           COMPUTER VISION        133

6.5.1        ELEVATED DEMAND FOR PRECISION MEDICINE TO DRIVE MARKET 133

6.6           IMAGE ANALYSIS              134

6.6.1        AUTOMATION OF COMPLEX IMAGING TASKS TO DRIVE MARKET               134

7               AI IN ONCOLOGY MARKET, BY APPLICATION    136

7.1           INTRODUCTION              137

7.2           DRUG DISCOVERY           138

7.2.1        TARGET IDENTIFICATION & VALIDATION           139

7.2.1.1    Emphasis on avoiding last-stage failure in drug discovery to boost growth    139

7.2.2        HIT IDENTIFICATION & PRIORITIZATION            141

7.2.2.1    Need for large-scale data analysis in HTS screening to drive adoption 141

7.2.3        HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION                 142

7.2.3.1    AI-driven lead generation to improve selectivity and binding mechanisms           142

7.2.4        LEAD OPTIMIZATION   143

7.2.4.1    Need to accelerate make-design-test cycles and high possibility of clinical drug failure to spur market    143

7.2.5        CANDIDATE SELECTION & VALIDATION              144

7.2.5.1    Candidate selection and validation to facilitate early drug discovery                144

7.3           DRUG DEVELOPMENT  145

7.3.1        PRECLINICAL TESTING 147

7.3.1.1    Need to identify risks and optimize candidates to boost growth                 147

7.3.2        PREDICTIVE MODELING FOR HUMAN TRIALS   148

7.3.2.1    Need for leveraging AI for accurate dose selection and safety assessments to boost growth               148

7.3.3        CLINICAL TRIAL OPTIMIZATION              149

7.3.3.1    Need to enhance trial efficiency and outcomes with AI-driven insights to propel market    149

7.3.4        ADAPTIVE TRIAL DESIGN & MONITORING          150

7.3.4.1    AI-driven adaptive trial design & monitoring help improve flexibility and success rates 150

7.4           DIAGNOSIS & EARLY DETECTION            151

7.4.1        IMAGING & RADIOLOGY               152

7.4.1.1    Mammography      154

7.4.1.1.1 Need for accurate diagnosis of breast cancer to propel market                 154

7.4.1.2    Computed tomography (CT)              154

7.4.1.2.1 Need for early diagnosis of solid tumors in lungs, liver, and brain to drive growth      154

7.4.1.3    Magnetic resonance imaging (MRI) 155

7.4.1.3.1 Need for optimizing imaging and enhancing tumor detection by integrating AI into MRI to propel demand       155

7.4.1.4    Nuclear imaging   156

7.4.1.4.1 Need for empowering AI-enhanced PET and SPECT imaging for precision oncology to drive growth    156

7.4.1.5    X-ray Imaging       157

7.4.1.5.1 Integrating AI-powered X-rays to automate detection of lung nodules to boost market      157

7.4.1.6    Ultrasound             158

7.4.1.6.1 Focus on integrating AI with ultrasound imaging to boost growth                 158

7.4.1.7    Other imaging modalities   159

7.4.2        DIGITAL PATHOLOGY & HISTOPATHOLOGY     160

7.4.2.1    Focus on examining tissue samples to diagnose diseases to boost market    160

7.4.3        LIQUID BIOPSY & BIOMARKER DETECTION        161

7.4.3.1    Advancements in non-invasive diagnostic technologies to propel growth    161

7.4.4        GENETIC RISK PREDICTION       162

7.4.4.1    Increased awareness of people regarding hereditary cancer risk to encourage growth 162

7.5           TREATMENT PLANNING & PERSONALIZATION 163

7.5.1        PERSONALIZED TREATMENT PLANNING             164

7.5.1.1    Precision medicine & genomic analysis            166

7.5.1.1.1 Need for adopting personalized therapies to improve treatment response to boost growth    166

7.5.1.2    Radiomics & radiogenomics                167

7.5.1.2.1 Emphasis on optimizing radiomics and radiogenomics for disease characterization to propel demand    167

7.5.1.3    Predictive models for treatment response        168

7.5.1.3.1 Adoption of predictive modeling to analyze genetic information to improve growth                 168

7.5.1.4    Treatment recommendation systems                168

7.5.1.4.1 Need for enhancing treatment decisions with data-driven insights to propel growth   168

7.5.2        RADIATION THERAPY   169

7.5.2.1    Need for effective tumor targeting to boost growth        169

7.5.3        CHEMOTHERAPY             170

7.5.3.1    Focus on optimizing chemotherapy for targeted treatment and risk prediction to boost segmental growth        170

7.5.4        IMMUNOTHERAPY          171

7.5.4.1    Use of immunotherapy for personalized and effective cancer care to boost growth     171

7.5.5        TARGETED THERAPY    172

7.5.5.1    Combination & dose optimization     173

7.5.5.1.1 Need for enhancing personalized dosing to augment segment growth    173

7.5.5.2    AI-guided drug delivery       174

7.5.5.2.1 Emphasis on achieving robust AI-powered drug delivery system to drive market      174

7.5.6        SURGICAL PLANNING & ASSISTANCE     175

7.5.6.1    Preoperative imaging & 3D modeling               176

7.5.6.1.1 AI-driven 3D models for enhanced oncology care          176

7.5.6.2    Intraoperative guidance and robotics                177

7.5.6.2.1 Focus on integrating robotic surgery to enhance precision in treatment to drive market   177

7.5.6.3    Postoperative analysis & recovery      178

7.5.6.3.1 Emphasis on enhancing AI in postoperative care to drive demand                 178

7.6           PATIENT ENGAGEMENT & REMOTE MONITORING                 179

7.6.1        SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE                 180

7.6.1.1    Symptom management & virtual assistance tools are beneficial for chronic disease management        180

7.6.2        REMOTE PATIENT MONITORING             181

7.6.2.1    Need for AI-enhanced, real-time monitoring to augment growth                 181

7.6.3        PATIENT EDUCATION & EMPOWERMENT            182

7.6.3.1    Improved health literacy and engagement with AI-curated insights  182

7.7           POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE     183

7.7.1        RECURRENCE MONITORING      184

7.7.1.1    Need to improve cancer surveillance and accurate recurrence detection and prognosis to drive market           184

7.7.2        LONG-TERM OUTCOME PREDICTION   186

7.7.2.1    Need for personalized care plans and chronic side-effect management to augment market       186

7.7.3        MENTAL HEALTH & SUPPORT SYSTEMS                187

7.7.3.1    Prioritizing mental health support in cancer care to augment segmental growth 187

7.8           DATA MANAGEMENT & ANALYTICS        188

7.8.1        INTEGRATION OF GENOMIC AND CLINICAL DATA TO ACCELERATE DEMAND FOR AI-POWERED ANALYTICS  188

7.9           OTHER APPLICATIONS 189

8               AI IN ONCOLOGY MARKET, BY CANCER TYPE    190

8.1           INTRODUCTION              191

8.2           SOLID TUMORS                 191

8.2.1        RISING PREVALENCE OF SOLID TUMORS TO BOOST NEED  FOR AI-DRIVEN INNOVATIONS 191

8.2.2        BREAST CANCER              193

8.2.3        LUNG CANCER  194

8.2.4        PROSTATE CANCER        195

8.2.5        COLORECTAL CANCER 196

8.2.6        BRAIN TUMOR  197

8.2.7        OTHER SOLID TUMORS                 198

8.3           HEMATOLOGIC MALIGNANCIES               199

8.3.1        RISING CASES OF BLOOD CANCER TO DRIVE MARKET                 199

8.3.2        LEUKEMIA          201

8.3.3        LYMPHOMA       202

8.3.4        MULTIPLE MYELOMA    203

8.3.5        OTHER HEMATOLOGIC MALIGNANCIES               204

8.4           OTHER CANCER TYPES 205

9               AI IN ONCOLOGY MARKET, BY END USER            206

9.1           INTRODUCTION              207

9.2           HEALTHCARE PROVIDERS           207

9.2.1        NEED FOR IMPROVED DIAGNOSTIC ACCURACY, PERSONALIZED TREATMENT PLANNING, AND ENHANCED WORKFLOW EFFICIENCY TO BOOST MARKET    207

9.2.2        HOSPITALS & CLINICS   209

9.2.3        SPECIALTY CENTERS     210

9.2.4        LABORATORIES & DIAGNOSTIC CENTERS            211

9.2.5        OTHER HEALTHCARE PROVIDERS           212

9.3           PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES                 213

9.3.1        NEED TO LEVERAGE AI FOR ACCELERATED ONCOLOGY DRUG DISCOVERY AND CLINICAL TRIALS TO BOOST GROWTH                 213

9.4           MEDICAL DEVICE/ EQUIPMENT COMPANIES     214

9.5           ACADEMIC & RESEARCH INSTITUTIONS               216

9.6           GOVERNMENT & REGULATORY AGENCIES          217

9.7           HEALTHCARE PAYERS   218

9.8           OTHER END USERS         219

10            AI IN ONCOLOGY MARKET, BY PLAYER TYPE     221

10.1         INTRODUCTION              222

10.2         NICHE/POINT SOLUTION PROVIDERS   222

10.2.1      NICHE/POINT SOLUTION PROVIDERS ACCELERATE CANCER DRUG DISCOVERY AND DEVELOPMENT            222

10.3         INTEGRATED SUITE/PLATFORM PROVIDERS     224

10.3.1      INTEGRATED SUITE/PLATFORM PROVIDERS REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS     224

10.4         TECHNOLOGY PROVIDERS         225

10.4.1      DEMAND FOR IMPROVED ONCOLOGY WORKFLOWS TO DRIVE MARKET 225

10.5         BUSINESS PROCESS SERVICE PROVIDERS             227

10.5.1      FOCUS ON OPTIMIZING NON-CLINICAL ONCOLOGY WORKFLOWS TO PROPEL MARKET GROWTH     227

11            AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL                 228

11.1         INTRODUCTION              229

11.2         CLOUD-BASED MODEL 229

11.2.1      NEED FOR ADVANCED CANCER RESEARCH AND TREATMENT TO BOOST USE OF CLOUD-BASED AI PLATFORMS                 229

11.3         ON-PREMISES MODEL   231

11.3.1      NEED FOR ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISES MODEL                 231

11.4         HYBRID MODEL                232

11.4.1      NEED FOR ENHANCING SCALABILITY AND DATA SECURITY IN DIAGNOSTICS TO DRIVE USE OF HYBRID-BASED AI PLATFORMS 232

12            AI IN ONCOLOGY MARKET, BY REGION 234

12.1         INTRODUCTION              235

12.2         NORTH AMERICA             236

12.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 239

12.2.2      US           249

12.2.2.1  Rising number of clinical trials and drug discovery to drive market                 249

12.2.3      CANADA               260

12.2.3.1  Pharmaceutical giants advancing innovation and expanding access to clinical trials to fuel market                 260

12.3         EUROPE               271

12.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      272

12.3.2      GERMANY           283

12.3.2.1  Advanced healthcare system and collaborative efforts to boost market    283

12.3.3      UK          293

12.3.3.1  Government support for developing new AI platforms to drive innovation              293

12.3.4      FRANCE                304

12.3.4.1  Growing R&D pipeline for oncology trials to drive market                 304

12.3.5      ITALY    314

12.3.5.1  Favorable regulatory scenarios to propel AI adoption in oncology                 314

12.3.6      SPAIN    325

12.3.6.1  Established network of research centers to propel market                 325

12.3.7      REST OF EUROPE             336

12.4         ASIA PACIFIC     346

12.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 347

12.4.2      CHINA  359

12.4.2.1  Increasing healthcare expenditure to drive demand for oncology solutions 359

12.4.3      INDIA    369

12.4.3.1  Growing cancer burden and healthcare disparities to fuel adoption of AI in oncology  369

12.4.4      JAPAN   380

12.4.4.1  Aging population and rising cancer rates to drive growth                 380

12.4.5      REST OF ASIA PACIFIC   390

12.5         LATIN AMERICA                401

12.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 402

12.5.2      BRAZIL 412

12.5.2.1  Rising cases of breast cancer to support market growth 412

12.5.3      MEXICO                422

12.5.3.1  Use of AI in pediatric cancer treatment and chemotherapy complications to fuel market growth 422

12.5.4      REST OF LATIN AMERICA             432

12.6         MIDDLE EAST & AFRICA                443

12.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 444

12.6.2      GCC COUNTRIES              454

12.6.2.1  Growing cancer cases and increasing clinical trials to drive growth                 454

12.6.3      REST OF MIDDLE EAST & AFRICA             465

13            COMPETITIVE LANDSCAPE         476

13.1         INTRODUCTION              476

13.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            476

13.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS                 477

13.3         REVENUE ANALYSIS OF KEY PLAYERS    478

13.4         MARKET SHARE ANALYSIS           479

13.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023                 481

13.5.1      STARS   481

13.5.2      EMERGING LEADERS     481

13.5.3      PERVASIVE PLAYERS      481

13.5.4      PARTICIPANTS 481

13.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2023         483

13.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023        488

13.6.1      PROGRESSIVE COMPANIES         488

13.6.2      RESPONSIVE COMPANIES            488

13.6.3      DYNAMIC COMPANIES  488

13.6.4      STARTING BLOCKS         488

13.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023                 490

13.7         COMPANY VALUATION AND FINANCIAL METRICS                 492

13.8         BRAND/SOFTWARE COMPARISON           493

13.9         COMPETITIVE SCENARIO             493

13.9.1      PRODUCT LAUNCHES & ENHANCEMENTS           493

13.9.2      DEALS  494

13.9.3      EXPANSIONS     495

13.9.4      OTHER DEVELOPMENTS              495

14            COMPANY PROFILES      496

14.1         KEY PLAYERS     496

14.1.1      NVIDIA CORPORATION 496

14.1.1.1  Business overview 496

14.1.1.2  Products/Solutions offered 497

14.1.1.3  Recent developments           498

14.1.1.3.1                Deals      498

14.1.1.4  MnM view              498

14.1.1.4.1                Right to win           498

14.1.1.4.2                Strategic choices   499

14.1.1.4.3                Weaknesses and competitive threats 499

14.1.2      GE HEALTHCARE             500

14.1.2.1  Business overview 500

14.1.2.2  Products/Solutions offered 501

14.1.2.3  Recent developments           502

14.1.2.3.1                Product launches & approvals            502

14.1.2.3.2                Deals      502

14.1.2.4  MnM view              503

14.1.2.4.1                Right to win           503

14.1.2.4.2                Strategic choices   503

14.1.2.4.3                Weaknesses and competitive threats 503

14.1.3      SIEMENS HEALTHINEERS AG      504

14.1.3.1  Business overview 504

14.1.3.2  Products/Solutions offered 505

14.1.3.3  Recent developments           506

14.1.3.3.1                Product launches & approvals            506

14.1.3.3.2                Deals      506

14.1.3.3.3                Expansions             506

14.1.3.4  MnM view              507

14.1.3.4.1                Right to win           507

14.1.3.4.2                Strategic choices   507

14.1.3.4.3                Weaknesses and competitive threats 507

14.1.4      F. HOFFMANN-LA ROCHE LTD  508

14.1.4.1  Business overview 508

14.1.4.2  Products/Solutions offered 509

14.1.4.3  Recent developments           510

14.1.4.3.1                Product launches & approvals            510

14.1.4.3.2                Deals      510

14.1.4.4  MnM view              511

14.1.4.4.1                Right to win           511

14.1.4.4.2                Strategic choices   511

14.1.4.4.3                Weaknesses and competitive threats 511

14.1.5      INSILICO MEDICINE       512

14.1.5.1  Business overview 512

14.1.5.2  Products/Solutions offered 512

14.1.5.3  Recent developments           513

14.1.5.4  MnM view              520

14.1.5.4.1                Right to win           520

14.1.5.4.2                Strategic choices   520

14.1.5.4.3                Weaknesses and competitive threats 520

14.1.6      CONCERTAI       521

14.1.6.1  Business overview 521

14.1.6.2  Products/Solutions offered 521

14.1.6.3  Recent developments           522

14.1.6.3.1                Product launches & approvals            522

14.1.6.3.2                Deals      522

14.1.7      MEDTRONIC      523

14.1.7.1  Business overview 523

14.1.7.2  Products/Solutions offered 524

14.1.7.3  Recent developments           525

14.1.7.3.1                Product launches & approvals            525

14.1.7.3.2                Deals      525

14.1.8      ORACLE                526

14.1.8.1  Business overview 526

14.1.8.2  Products/Solutions offered 527

14.1.8.3  Recent developments           528

14.1.8.3.1                Product launches & approvals            528

14.1.8.3.2                Deals      528

14.1.9      KONINKLIJKE PHILIPS N.V.          529

14.1.9.1  Business overview 529

14.1.9.2  Products/Solutions offered 530

14.1.9.3  Recent developments           531

14.1.9.3.1                Deals      531

14.1.10   PREDICTIVE ONCOLOGY             532

14.1.10.1                 Business overview 532

14.1.10.2                 Products/Solutions offered 533

14.1.10.3                 Recent developments           533

14.1.10.3.1             Product launches & approvals            533

14.1.10.3.2             Deals      533

14.1.11   EXSCIENTIA       534

14.1.11.1                 Business overview 534

14.1.11.2                 Products/Solutions offered 535

14.1.11.3                 Recent developments           536

14.1.11.3.1             Product launches & approvals            536

14.1.11.3.2             Deals      536

14.1.11.3.3             Expansions             541

14.1.11.3.4             Other developments             542

14.1.12   PATHAI, INC.     543

14.1.12.1                 Business overview 543

14.1.12.2                 Products/Solutions offered 543

14.1.12.3                 Recent developments           544

14.1.12.3.1             Product launches & approvals            544

14.1.12.3.2             Deals      544

14.1.13   CUREMETRIX, INC.          545

14.1.13.1                 Business overview 545

14.1.13.2                 Products/Solutions offered 545

14.1.13.3                 Recent developments           545

14.1.13.3.1             Other developments             545

14.1.14   MINDPEAK GMBH            546

14.1.14.1                 Business overview 546

14.1.14.2                 Products/Solutions offered 546

14.1.14.3                 Recent developments           547

14.1.14.3.1             Product launches & approvals            547

14.1.14.3.2             Deals      547

14.1.14.3.3             Other developments             547

14.1.15   PAIGE AI, INC.   548

14.1.15.1                 Business overview 548

14.1.15.2                 Products/Solutions offered 548

14.1.15.3                 Recent developments           549

14.1.15.3.1             Product launches & approvals            549

14.1.15.3.2             Deals      549

14.1.15.3.3             Other developments             550

14.1.16   TEMPUS AI, INC.               551

14.1.16.1                 Business overview 551

14.1.16.2                 Products/Solutions offered 551

14.1.16.3                 Recent developments           552

14.1.16.3.1             Product launches & approvals            552

14.1.16.3.2             Deals      553

14.1.16.3.3             Expansions             555

14.1.16.3.4             Other developments             556

14.1.17   IKTOS   557

14.1.17.1                 Business overview 557

14.1.17.2                 Products/Solutions offered 557

14.1.17.3                 Recent developments           558

14.1.17.3.1             Deals      558

14.1.17.3.2             Other developments             561

14.2         OTHER PLAYERS              562

14.2.1      AZRA AI                562

14.2.2      CUREMATCH, INC.          563

14.2.3      ONCOLENS         563

14.2.4      TRIOMICS            564

14.2.5      CLINAKOS           565

14.2.6      PERTHERA, INC.                566

14.2.7      CELLWORKS GROUP, INC.            566

14.2.8      BIOMY, INC.       567

15            APPENDIX           568

15.1         DISCUSSION GUIDE        568

15.2         KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL                577

15.3         CUSTOMIZATION OPTIONS        579

15.4         RELATED REPORTS         579

15.5         AUTHOR DETAILS           580

LIST OF TABLES

TABLE 1                USD EXCHANGE RATES, 2021–2023            51

TABLE 2                FACTOR ANALYSIS          65

TABLE 3                AI IN ONCOLOGY MARKET: RISK ASSESSMENT                 70

TABLE 4                AI IN ONCOLOGY MARKET: IMPACT ANALYSIS                 85

TABLE 5                AI IN ONCOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM       90

TABLE 6                IMPACT OF PORTER’S FIVE FORCES ON AI IN ONCOLOGY MARKET     96

TABLE 7                NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  100

TABLE 8                EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  101

TABLE 9                ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  102

TABLE 10              LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  102

TABLE 11              MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS  103

TABLE 12              JURISDICTION ANALYSIS OF TOP PATENT APPLICANT COUNTRIES FOR AI IN ONCOLOGY                 104

TABLE 13              AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION,

2023 (USD THOUSAND) 110

TABLE 14              AI IN ONCOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025           110

TABLE 15              INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS (%)         111

TABLE 16              KEY BUYING CRITERIA FOR TOP 3 END USERS                 112

TABLE 17              UNMET NEEDS IN AI IN ONCOLOGY MARKET                 113

TABLE 18              END USER EXPECTATIONS IN AI IN ONCOLOGY MARKET               114

TABLE 19              AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            121

TABLE 20              AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            123

TABLE 21              AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY REGION,

2022–2030 (USD MILLION)            124

TABLE 22              AI IN ONCOLOGY MARKET FOR DEEP LEARNING, BY REGION,

2022–2030 (USD MILLION)            127

TABLE 23              AI IN ONCOLOGY MARKET FOR SUPERVISED LEARNING, BY REGION,

2022–2030 (USD MILLION)            128

TABLE 24              AI IN ONCOLOGY MARKET FOR REINFORCEMENT LEARNING, BY REGION,

2022–2030 (USD MILLION)            129

TABLE 25              AI IN ONCOLOGY MARKET FOR UNSUPERVISED LEARNING, BY REGION,

2022–2030 (USD MILLION)            130

TABLE 26              AI IN ONCOLOGY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES,

BY REGION, 2022–2030 (USD MILLION)   131

TABLE 27              AI IN ONCOLOGY MARKET FOR NATURAL LANGUAGE PROCESSING,

BY REGION,  2022–2030 (USD MILLION)                 132

TABLE 28              AI IN ONCOLOGY MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING,  BY REGION, 2022–2030 (USD MILLION) 133

TABLE 29              AI IN ONCOLOGY MARKET FOR COMPUTER VISION, BY REGION,

2022–2030 (USD MILLION)            134

TABLE 30              AI IN ONCOLOGY MARKET FOR IMAGE ANALYSIS, BY REGION,

2022–2030 (USD MILLION)            135

TABLE 31              AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)            137

TABLE 32              AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            138

TABLE 33              AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY REGION,

2022–2030 (USD MILLION)            139

TABLE 34              AI IN ONCOLOGY MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY REGION, 2022–2030 (USD MILLION)            140

TABLE 35              AI IN ONCOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION,  2022–2030 (USD MILLION) 141

TABLE 36              AI IN ONCOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION,  BY REGION, 2022–2030 (USD MILLION) 143

TABLE 37              AI IN ONCOLOGY MARKET FOR LEAD OPTIMIZATION, BY REGION,

2022–2030 (USD MILLION)            144

TABLE 38              AI IN ONCOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION,  2022–2030 (USD MILLION)            145

TABLE 39              AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            146

TABLE 40              AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY REGION,

2022–2030 (USD MILLION)            146

TABLE 41              AI IN ONCOLOGY MARKET FOR PRECLINICAL TESTING, BY REGION,

2022–2030 (USD MILLION)            147

TABLE 42              AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELING FOR HUMAN TRIALS,

BY REGION, 2022–2030 (USD MILLION)   148

TABLE 43              AI IN ONCOLOGY MARKET FOR CLINICAL TRIAL OPTIMIZATION, BY REGION,

2022–2030 (USD MILLION)            149

TABLE 44              AI IN ONCOLOGY MARKET FOR ADAPTIVE TRIAL DESIGN & MONITORING,

BY REGION, 2022–2030 (USD MILLION)   150

TABLE 45              AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE,

2022–2030 (USD MILLION)            151

TABLE 46              AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY REGION,  2022–2030 (USD MILLION)                 152

TABLE 47              AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            153

TABLE 48              AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY REGION,

2022–2030 (USD MILLION)            153

TABLE 49              AI IN ONCOLOGY MARKET FOR MAMMOGRAPHY, BY REGION,

2022–2030 (USD MILLION)            154

TABLE 50              AI IN ONCOLOGY MARKET FOR COMPUTED TOMOGRAPHY, BY REGION,

2022–2030 (USD MILLION)            155

TABLE 51              AI IN ONCOLOGY MARKET FOR MAGNETIC RESONANCE IMAGING (MRI),

BY REGION, 2022–2030 (USD MILLION)   156

TABLE 52              AI IN ONCOLOGY MARKET FOR NUCLEAR IMAGING, BY REGION,

2022–2030 (USD MILLION)            157

TABLE 53             AI IN ONCOLOGY MARKET FOR X-RAY IMAGING, BY REGION,

2022–2030 (USD MILLION)            158

TABLE 54              AI IN ONCOLOGY MARKET FOR ULTRASOUND, BY REGION,

2022–2030 (USD MILLION)            159

TABLE 55              AI IN ONCOLOGY MARKET FOR OTHER IMAGING MODALITIES, BY REGION,

2022–2030 (USD MILLION)            159

TABLE 56              AI IN ONCOLOGY MARKET FOR DIGITAL PATHOLOGY & HISTOPATHOLOGY,

BY REGION, 2022–2030 (USD MILLION)   160

TABLE 57              AI IN ONCOLOGY MARKET FOR LIQUID BIOPSY & BIOMARKER DETECTION,

BY REGION, 2022–2030 (USD MILLION)   161

TABLE 58              AI IN ONCOLOGY MARKET FOR GENETIC RISK PREDICTION, BY REGION,

2022–2030 (USD MILLION)            162

TABLE 59              AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,

BY TYPE, 2022–2030 (USD MILLION)         163

TABLE 60              AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,

BY REGION, 2022–2030 (USD MILLION)   164

TABLE 61              AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE,  2022–2030 (USD MILLION)      165

TABLE 62              AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY REGION, 2022–2030 (USD MILLION)   165

TABLE 63              AI IN ONCOLOGY MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS,

BY REGION, 2022–2030 (USD MILLION) 166

TABLE 64              AI IN ONCOLOGY MARKET FOR RADIOMICS & RADIOGENOMICS,

BY REGION,  2022–2030 (USD MILLION)                 167

TABLE 65              AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE,  BY REGION, 2022–2030 (USD MILLION) 168

TABLE 66              AI IN ONCOLOGY MARKET FOR TREATMENT RECOMMENDATION SYSTEMS,

BY REGION, 2022–2030 (USD MILLION)   169

TABLE 67              AI IN ONCOLOGY MARKET FOR RADIATION THERAPY, BY REGION,

2022–2030 (USD MILLION)            170

TABLE 68              AI IN ONCOLOGY MARKET FOR CHEMOTHERAPY, BY REGION,

2022–2030 (USD MILLION)            171

TABLE 69              AI IN ONCOLOGY MARKET FOR IMMUNOTHERAPY, BY REGION,

2022–2030 (USD MILLION)            172

TABLE 70              AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            172

TABLE 71              AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY REGION,

2022–2030 (USD MILLION)            173

TABLE 72              AI IN ONCOLOGY MARKET FOR COMBINATION & DOSE OPTIMIZATION,

BY REGION,  2022–2030 (USD MILLION)                 174

TABLE 73              AI IN ONCOLOGY MARKET FOR AI-GUIDED DRUG DELIVERY, BY REGION,

2022–2030 (USD MILLION)            175

TABLE 74              AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE,  2022–2030 (USD MILLION)      176

TABLE 75              AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY REGION,  2022–2030 (USD MILLION)            176

TABLE 76              AI IN ONCOLOGY MARKET FOR PREOPERATIVE IMAGING & 3D MODELING,

BY REGION, 2022–2030 (USD MILLION)   177

TABLE 77              AI IN ONCOLOGY MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS,

BY REGION, 2022–2030 (USD MILLION)   178

TABLE 78              AI IN ONCOLOGY MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY,

BY REGION, 2022–2030 (USD MILLION)   179

TABLE 79              AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 180

TABLE 80              AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING,  BY REGION, 2022–2030 (USD MILLION)       180

TABLE 81              AI IN ONCOLOGY MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE,  BY REGION, 2022–2030 (USD MILLION)       181

TABLE 82              AI IN ONCOLOGY MARKET FOR REMOTE PATIENT MONITORING, BY REGION,  2022–2030 (USD MILLION)            182

TABLE 83              AI IN ONCOLOGY MARKET FOR PATIENT EDUCATION & EMPOWERMENT,

BY REGION, 2022–2030 (USD MILLION)   183

TABLE 84              AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            184

TABLE 85              AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2022–2030 (USD MILLION)          184

TABLE 86              AI IN ONCOLOGY MARKET FOR RECURRENCE MONITORING, BY REGION,

2022–2030 (USD MILLION)            185

TABLE 87              AI IN ONCOLOGY MARKET FOR LONG-TERM OUTCOME PREDICTION,

BY REGION,  2022–2030 (USD MILLION)                 186

TABLE 88              AI IN ONCOLOGY MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS,

BY REGION, 2022–2030 (USD MILLION)   187

TABLE 89              AI IN ONCOLOGY MARKET FOR DATA MANAGEMENT & ANALYTICS, BY REGION,  2022–2030 (USD MILLION)            188

TABLE 90              AI IN ONCOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION,

2022–2030 (USD MILLION)            189

TABLE 91              AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)            191

TABLE 92              AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            192

TABLE 93              AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY REGION,

2022–2030 (USD MILLION)            193

TABLE 94              AI IN ONCOLOGY MARKET FOR BREAST CANCER, BY REGION,

2022–2030 (USD MILLION)            194

TABLE 95              AI IN ONCOLOGY MARKET FOR LUNG CANCER, BY REGION,

2022–2030 (USD MILLION)            195

TABLE 96              AI IN ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION,

2022–2030 (USD MILLION)            196

TABLE 97              AI IN ONCOLOGY MARKET FOR COLORECTAL CANCER, BY REGION,

2022–2030 (USD MILLION)            197

TABLE 98              AI IN ONCOLOGY MARKET FOR BRAIN TUMORS, BY REGION,

2022–2030 (USD MILLION)            198

TABLE 99              AI IN ONCOLOGY MARKET FOR OTHER SOLID TUMORS, BY REGION,

2022–2030 (USD MILLION)            199

TABLE 100            AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE,

2022–2030 (USD MILLION)            200

TABLE 101            AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION,  2022–2030 (USD MILLION) 201

TABLE 102            AI IN ONCOLOGY MARKET FOR LEUKEMIA, BY REGION, 2022–2030 (USD MILLION)          202

TABLE 103            AI IN ONCOLOGY MARKET FOR LYMPHOMA, BY REGION,

2022–2030 (USD MILLION)            203

TABLE 104            AI IN ONCOLOGY MARKET FOR MULTIPLE MYELOMA, BY REGION,

2022–2030 (USD MILLION)            204

TABLE 105            AI IN ONCOLOGY MARKET FOR OTHER HEMATOLOGICAL MALIGNANCIES,

BY REGION, 2022–2030 (USD MILLION)   204

TABLE 106            AI IN ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION,

2022–2030 (USD MILLION)            205

TABLE 107            AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)       207

TABLE 108            AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            208

TABLE 109            AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION,

2022–2030 (USD MILLION)            209

TABLE 110            AI IN ONCOLOGY MARKET FOR HOSPITALS & CLINICS, BY REGION,

2022–2030 (USD MILLION)            210

TABLE 111            AI IN ONCOLOGY MARKET FOR SPECIALTY CENTERS, BY REGION,

2022–2030 (USD MILLION)            211

TABLE 112            AI IN ONCOLOGY MARKET FOR LABORATORIES & DIAGNOSTIC CENTERS,

BY REGION, 2022–2030 (USD MILLION)   212

TABLE 113            AI IN ONCOLOGY MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION,  2022–2030 (USD MILLION)            212

TABLE 114            AI IN ONCOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES,  BY REGION, 2022–2030 (USD MILLION)          214

TABLE 115            AI IN ONCOLOGY MARKET FOR MEDICAL DEVICE/ EQUIPMENT COMPANIES,

BY REGION, 2022–2030 (USD MILLION) 215

TABLE 116            AI IN ONCOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022–2030 (USD MILLION)            216

TABLE 117            AI IN ONCOLOGY MARKET FOR GOVERNMENT & REGULATORY AGENCIES,

BY REGION, 2022–2030 (USD MILLION)   218

TABLE 118            AI IN ONCOLOGY MARKET FOR HEALTHCARE PAYERS, BY REGION,

2022–2030 (USD MILLION)            219

TABLE 119            AI IN ONCOLOGY MARKET FOR OTHER END USERS, BY REGION,

2022–2030 (USD MILLION)            220

TABLE 120            AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)            222

TABLE 121            AI IN ONCOLOGY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION,  2022–2030 (USD MILLION)                 223

TABLE 122            AI IN ONCOLOGY MARKET FOR INTEGRATED SUITE/PLATFORM PROVIDERS,

BY REGION, 2022–2030 (USD MILLION)   225

TABLE 123            AI IN ONCOLOGY MARKET FOR TECHNOLOGY PROVIDERS, BY REGION,

2022–2030 (USD MILLION)            226

TABLE 124            AI IN ONCOLOGY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS,

BY REGION, 2022–2030 (USD MILLION)   227

TABLE 125            AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,  2022–2030 (USD MILLION)       229

TABLE 126            AI IN ONCOLOGY MARKET FOR CLOUD-BASED MODEL,  BY REGION,

2022–2030 (USD MILLION)            231

TABLE 127            AI IN ONCOLOGY MARKET FOR ON-PREMISES MODEL,  BY REGION,

2022–2030 (USD MILLION)            232

TABLE 128          AI IN ONCOLOGY MARKET FOR HYBRID MODEL, BY REGION,

2022–2030 (USD MILLION)            233

TABLE 129            AI IN ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION)       236

TABLE 130            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY,

2022–2030 (USD MILLION)          239

TABLE 131            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            240

TABLE 132            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)          240

TABLE 133            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,  2022–2030 (USD MILLION)                 241

TABLE 134            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            241

TABLE 135            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,  2022–2030 (USD MILLION)                 242

TABLE 136            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,  2022–2030 (USD MILLION)            242

TABLE 137            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,  BY TYPE, 2022–2030 (USD MILLION) 243

TABLE 138            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)            243

TABLE 139            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)            244

TABLE 140            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)       244

TABLE 141            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,  2022–2030 (USD MILLION)                 245

TABLE 142            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 245

TABLE 143            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)                246

TABLE 144            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)         246

TABLE 145            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            247

TABLE 146            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,

BY TYPE, 2022–2030 (USD MILLION)         247

TABLE 147            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,  BY TYPE, 2022–2030 (USD MILLION) 248

TABLE 148            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            248

TABLE 149            NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2022–2030 (USD MILLION)         249

TABLE 150            NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            249

TABLE 151          US: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)            251

TABLE 152            US: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            251

TABLE 153            US: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,  2022–2030 (USD MILLION)              252

TABLE 154            US: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              252

TABLE 155            US: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            253

TABLE 156            US: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            253

TABLE 157            US: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE,  2022–2030 (USD MILLION)                 254

TABLE 158            US: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            254

TABLE 159            US: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       255

TABLE 160            US: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         255

TABLE 161            US: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            256

TABLE 162            US: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE,  2022–2030 (USD MILLION)      256

TABLE 163            US: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING,  BY TYPE, 2022–2030 (USD MILLION) 257

TABLE 164            US: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            257

TABLE 165            US: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                258

TABLE 166            US: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            258

TABLE 167            US: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         259

TABLE 168            US: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)            259

TABLE 169            US: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            260

TABLE 170            US: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            260

TABLE 171            CANADA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)               262

TABLE 172            CANADA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            262

TABLE 173            CANADA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)          263

TABLE 174            CANADA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              263

TABLE 175            CANADA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            264

TABLE 176            CANADA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            264

TABLE 177            CANADA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)            265

TABLE 178            CANADA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            265

TABLE 179            CANADA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       266

TABLE 180            CANADA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,  BY TYPE, 2022–2030 (USD MILLION) 266

TABLE 181            CANADA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            267

TABLE 182            CANADA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         267

TABLE 183            CANADA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            268

TABLE 184            CANADA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            268

TABLE 185            CANADA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)             269

TABLE 186            CANADA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            269

TABLE 187            CANADA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         270

TABLE 188            CANADA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                270

TABLE 189            CANADA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,  2022–2030 (USD MILLION)                 271

TABLE 190            CANADA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            271

TABLE 191            EUROPE: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     273

TABLE 192            EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                273

TABLE 193            EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            274

TABLE 194            EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            274

TABLE 195            EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              275

TABLE 196            EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            275

TABLE 197            EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            276

TABLE 198            EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         276

TABLE 199            EUROPE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            277

TABLE 200            EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       277

TABLE 201            EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 278

TABLE 202            EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            278

TABLE 203            EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         279

TABLE 204            EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            279

TABLE 205            EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            280

TABLE 206            EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)             280

TABLE 207            EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            281

TABLE 208            EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         281

TABLE 209            EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                282

TABLE 210            EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,  2022–2030 (USD MILLION)                 282

TABLE 211            EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            283

TABLE 212            GERMANY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            284

TABLE 213            GERMANY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            284

TABLE 214            GERMANY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            285

TABLE 215            GERMANY: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            285

TABLE 216            GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            286

TABLE 217            GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            286

TABLE 218            GERMANY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         287

TABLE 219            GERMANY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,  2022–2030 (USD MILLION)                 287

TABLE 220            GERMANY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)       288

TABLE 221            GERMANY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,  BY TYPE, 2022–2030 (USD MILLION) 288

TABLE 222            GERMANY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            289

TABLE 223            GERMANY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         289

TABLE 224            GERMANY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            290

TABLE 225            GERMANY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)                290

TABLE 226            GERMANY: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            291

TABLE 227            GERMANY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            291

TABLE 228            GERMANY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         292

TABLE 229            GERMANY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                292

TABLE 230            GERMANY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,  2022–2030 (USD MILLION)                 293

TABLE 231            GERMANY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            293

TABLE 232            UK: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                294

TABLE 233            UK: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            295

TABLE 234            UK: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            295

TABLE 235            UK: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              296

TABLE 236            UK: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            296

TABLE 237            UK: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)          297

TABLE 238            UK: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         297

TABLE 239            UK: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            298

TABLE 240            UK: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)       298

TABLE 241            UK: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         299

TABLE 242            UK: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            299

TABLE 243            UK: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE,  2022–2030 (USD MILLION)      300

TABLE 244            UK: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING,  BY TYPE, 2022–2030 (USD MILLION) 300

TABLE 245            UK: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            301

TABLE 246            UK: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                301

TABLE 247            UK: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            302

TABLE 248            UK: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE,  2022–2030 (USD MILLION)      302

TABLE 249            UK: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)            303

TABLE 250            UK: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            303

TABLE 251            UK: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            304

TABLE 252            FRANCE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                305

TABLE 253            FRANCE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            305

TABLE 254            FRANCE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            306

TABLE 255            FRANCE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              306

TABLE 256            FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            307

TABLE 257            FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            307

TABLE 258            FRANCE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE,  2022–2030 (USD MILLION)            308

TABLE 259            FRANCE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            308

TABLE 260            FRANCE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       309

TABLE 261            FRANCE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 309

TABLE 262            FRANCE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            310

TABLE 263            FRANCE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         310

TABLE 264            FRANCE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            311

TABLE 265            FRANCE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            311

TABLE 266            FRANCE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)             312

TABLE 267            FRANCE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            312

TABLE 268            FRANCE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         313

TABLE 269            FRANCE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                313

TABLE 270            FRANCE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE,  2022–2030 (USD MILLION)      314

TABLE 271            FRANCE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            314

TABLE 272            ITALY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                316

TABLE 273            ITALY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            316

TABLE 274            ITALY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            317

TABLE 275            ITALY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              317

TABLE 276            ITALY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            318

TABLE 277            ITALY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            318

TABLE 278            ITALY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE,  2022–2030 (USD MILLION)    319

TABLE 279            ITALY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            319

TABLE 280            ITALY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       320

TABLE 281            ITALY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         320

TABLE 282            ITALY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            321

TABLE 283            ITALY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         321

TABLE 284            ITALY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING,  BY TYPE, 2022–2030 (USD MILLION) 322

TABLE 285            ITALY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            322

TABLE 286            ITALY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                323

TABLE 287            ITALY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            323

TABLE 288            ITALY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE,  2022–2030 (USD MILLION)      324

TABLE 289          ITALY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)            324

TABLE 290            ITALY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            325

TABLE 291            ITALY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            325

TABLE 292            SPAIN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                326

TABLE 293            SPAIN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            327

TABLE 294            SPAIN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            327

TABLE 295            SPAIN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              328

TABLE 296            SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            328

TABLE 297            SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            329

TABLE 298            SPAIN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         329

TABLE 299            SPAIN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            330

TABLE 300            SPAIN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       330

TABLE 301            SPAIN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         331

TABLE 302            SPAIN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            331

TABLE 303            SPAIN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         332

TABLE 304            SPAIN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 332

TABLE 305            SPAIN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            333

TABLE 306            SPAIN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                333

TABLE 307            SPAIN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            334

TABLE 308            SPAIN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE,  2022–2030 (USD MILLION)            334

TABLE 309          SPAIN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)            335

TABLE 310            SPAIN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            335

TABLE 311            SPAIN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            336

TABLE 312            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            337

TABLE 313            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            337

TABLE 314            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,

BY TYPE,  2022–2030 (USD MILLION)      338

TABLE 315            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            338

TABLE 316            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY,

BY TYPE, 2022–2030 (USD MILLION)         339

TABLE 317            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,  2022–2030 (USD MILLION)            339

TABLE 318            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,  BY TYPE, 2022–2030 (USD MILLION) 340

TABLE 319            REST OF EUROPE AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,  2022–2030 (USD MILLION)            340

TABLE 320            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)            341

TABLE 321            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)       341

TABLE 322            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,

BY TYPE,  2022–2030 (USD MILLION)      342

TABLE 323            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 342

TABLE 324            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)                343

TABLE 325            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)         343

TABLE 326            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            344

TABLE 327            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,

BY TYPE,  2022–2030 (USD MILLION)      344

TABLE 328            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,  BY TYPE, 2022–2030 (USD MILLION) 345

TABLE 329            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            345

TABLE 330            REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2022–2030 (USD MILLION)         346

TABLE 331            REST OF EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            346

TABLE 332            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     349

TABLE 333            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            349

TABLE 334            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            350

TABLE 335            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,

BY TYPE,  2022–2030 (USD MILLION)      350

TABLE 336            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            351

TABLE 337            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            351

TABLE 338            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,  2022–2030 (USD MILLION)                 352

TABLE 339            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         352

TABLE 340            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY,

BY TYPE, 2022–2030 (USD MILLION)         353

TABLE 341            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)       353

TABLE 342            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,  BY TYPE, 2022–2030 (USD MILLION) 354

TABLE 343            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,

BY TYPE,  2022–2030 (USD MILLION)      354

TABLE 344            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,  BY TYPE, 2022–2030 (USD MILLION)            355

TABLE 345            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            355

TABLE 346            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)                356

TABLE 347            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            356

TABLE 348            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            357

TABLE 349            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         357

TABLE 350            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            358

TABLE 351            ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE,  2022–2030 (USD MILLION)      358

TABLE 352            ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            359

TABLE 353            CHINA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                360

TABLE 354            CHINA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            360

TABLE 355            CHINA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            361

TABLE 356            CHINA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              361

TABLE 357            CHINA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            362

TABLE 358            CHINA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            362

TABLE 359            CHINA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE,  2022–2030 (USD MILLION)      363

TABLE 360            CHINA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            363

TABLE 361            CHINA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       364

TABLE 362            CHINA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         364

TABLE 363            CHINA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            365

TABLE 364            CHINA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         365

TABLE 365            CHINA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            366

TABLE 366            CHINA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            366

TABLE 367            CHINA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                367

TABLE 368            CHINA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            367

TABLE 369            CHINA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE,  2022–2030 (USD MILLION)      368

TABLE 370            CHINA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                368

TABLE 371            CHINA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            369

TABLE 372            CHINA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            369

TABLE 373            INDIA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                370

TABLE 374            INDIA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            371

TABLE 375            INDIA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            371

TABLE 376            INDIA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              372

TABLE 377            INDIA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            372

TABLE 378            INDIA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            373

TABLE 379            INDIA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         373

TABLE 380            INDIA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            374

TABLE 381            INDIA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       374

TABLE 382            INDIA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         375

TABLE 383            INDIA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            375

TABLE 384            INDIA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         376

TABLE 385            INDIA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING,  BY TYPE, 2022–2030 (USD MILLION) 376

TABLE 386            INDIA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            377

TABLE 387            INDIA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                377

TABLE 388            INDIA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            378

TABLE 389            INDIA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         378

TABLE 390          INDIA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)            379

TABLE 391            INDIA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            379

TABLE 392            INDIA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            380

TABLE 393            JAPAN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                381

TABLE 394            JAPAN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            381

TABLE 395            JAPAN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            382

TABLE 396            JAPAN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              382

TABLE 397            JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            383

TABLE 398            JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            383

TABLE 399            JAPAN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE,  2022–2030 (USD MILLION)            384

TABLE 400            JAPAN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)S          384

TABLE 401            JAPAN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       385

TABLE 402            JAPAN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         385

TABLE 403            JAPAN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            386

TABLE 404            JAPAN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         386

TABLE 405            JAPAN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            387

TABLE 406            JAPAN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            387

TABLE 407            JAPAN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                388

TABLE 408            JAPAN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            388

TABLE 409            JAPAN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE,  2022–2030 (USD MILLION)      389

TABLE 410            JAPAN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                389

TABLE 411            JAPAN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE,

2022–2030 (USD MILLION)            390

TABLE 412            JAPAN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            390

TABLE 413            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            391

TABLE 414            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            392

TABLE 415            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,

BY TYPE, 2022–2030 (USD MILLION)         392

TABLE 416            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            393

TABLE 417            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY,

BY TYPE, 2022–2030 (USD MILLION)         393

TABLE 418            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT,

BY TYPE, 2022–2030 (USD MILLION)         394

TABLE 419            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)       394

TABLE 420            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY,

BY TYPE, 2022–2030 (USD MILLION)         395

TABLE 421            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)         395

TABLE 422            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)                396

TABLE 423            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,

BY TYPE, 2022–2030 (USD MILLION)         396

TABLE 424            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)            397

TABLE 425            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)          397

TABLE 426            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)                 398

TABLE 427            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            398

TABLE 428            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,

BY TYPE,  2022–2030 (USD MILLION)      399

TABLE 429            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)            399

TABLE 430            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            400

TABLE 431            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 400

TABLE 432            REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,  2022–2030 (USD MILLION)                 401

TABLE 433            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            402

TABLE 434            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            403

TABLE 435            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            403

TABLE 436            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,  2022–2030 (USD MILLION)                 404

TABLE 437            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            404

TABLE 438            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,  2022–2030 (USD MILLION)                 405

TABLE 439            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT,  BY TYPE, 2022–2030 (USD MILLION)            405

TABLE 440            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)            406

TABLE 441            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY,

BY TYPE,  2022–2030 (USD MILLION)      406

TABLE 442            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)            407

TABLE 443            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)       407

TABLE 444            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,  BY TYPE, 2022–2030 (USD MILLION)                 408

TABLE 445            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,  BY TYPE, 2022–2030 (USD MILLION) 408

TABLE 446            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)                409

TABLE 447            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)         409

TABLE 448            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            410

TABLE 449            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            410

TABLE 450            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,  BY TYPE, 2022–2030 (USD MILLION) 411

TABLE 451            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            411

TABLE 452            LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2022–2030 (USD MILLION)         412

TABLE 453            LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            412

TABLE 454            BRAZIL: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                413

TABLE 455            BRAZIL: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            413

TABLE 456            BRAZIL: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            414

TABLE 457            BRAZIL: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              414

TABLE 458            BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            415

TABLE 459            BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)          415

TABLE 460            BRAZIL: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE,  2022–2030 (USD MILLION)      416

TABLE 461            BRAZIL: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            416

TABLE 462            BRAZIL: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       417

TABLE 463            BRAZIL: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING,

BY TYPE, 2022–2030 (USD MILLION)         417

TABLE 464            BRAZIL: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            418

TABLE 465            BRAZIL: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         418

TABLE 466            BRAZIL: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            419

TABLE 467            BRAZIL: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            419

TABLE 468            BRAZIL: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)                420

TABLE 469            BRAZIL: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            420

TABLE 470            BRAZIL: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)            421

TABLE 471            BRAZIL: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                421

TABLE 472            BRAZIL: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE,  2022–2030 (USD MILLION)      422

TABLE 473            BRAZIL: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            422

TABLE 474            MEXICO: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION)                423

TABLE 475            MEXICO: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)            423

TABLE 476            MEXICO: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE,

2022–2030 (USD MILLION)            424

TABLE 477            MEXICO: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION)              424

TABLE 478            MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,

2022–2030 (USD MILLION)            425

TABLE 479            MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,

2022–2030 (USD MILLION)            425

TABLE 480            MEXICO: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,

BY TYPE, 2022–2030 (USD MILLION)         426

TABLE 481            MEXICO: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,

2022–2030 (USD MILLION)            426

TABLE 482            MEXICO: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION,  BY TYPE, 2022–2030 (USD MILLION)       427

TABLE 483            MEXICO: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 427

TABLE 484            MEXICO: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,

2022–2030 (USD MILLION)            428

TABLE 485            MEXICO: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,

BY TYPE, 2022–2030 (USD MILLION)         428

TABLE 486            MEXICO: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)            429

TABLE 487            MEXICO: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)            429

TABLE 488            MEXICO: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION)             430

TABLE 489            MEXICO: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE,

2022–2030 (USD MILLION)            430

TABLE 490            MEXICO: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,

BY TYPE, 2022–2030 (USD MILLION)         431

TABLE 491            MEXICO: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION)                431

TABLE 492            MEXICO: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE,  2022–2030 (USD MILLION)      432

TABLE 493            MEXICO: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            432

TABLE 494            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            433

TABLE 495            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            434

TABLE 496            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,

BY TYPE, 2022–2030 (USD MILLION)         434

TABLE 497            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            435

TABLE 498            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY,

BY TYPE, 2022–2030 (USD MILLION)         435

TABLE 499            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT,

BY TYPE, 2022–2030 (USD MILLION)         436

TABLE 500            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)       436

TABLE 501            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY,  BY TYPE, 2022–2030 (USD MILLION) 437

TABLE 502            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)         437

TABLE 503            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)                438

TABLE 504            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,

BY TYPE, 2022–2030 (USD MILLION)         438

TABLE 505            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)            439

TABLE 506            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)          439

TABLE 507            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)                 440

TABLE 508            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            440

TABLE 509            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION)            441

TABLE 510            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)            441

TABLE 511            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            442

TABLE 512            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,  BY TYPE, 2022–2030 (USD MILLION) 442

TABLE 513            REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,  2022–2030 (USD MILLION)                 443

TABLE 514            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY COUNTRY,

2022–2030 (USD MILLION)            444

TABLE 515            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            445

TABLE 516            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            445

TABLE 517            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,

BY TYPE, 2022–2030 (USD MILLION)         446

TABLE 518            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            446

TABLE 519            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY,

BY TYPE, 2022–2030 (USD MILLION)         447

TABLE 520            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT,

BY TYPE, 2022–2030 (USD MILLION)         447

TABLE 521            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS &

EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)                 448

TABLE 522            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)            448

TABLE 523            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)         449

TABLE 524            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)                449

TABLE 525            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,

BY TYPE, 2022–2030 (USD MILLION)         450

TABLE 526            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)            450

TABLE 527            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)          451

TABLE 528            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)                 451

TABLE 529            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            452

TABLE 530            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,

BY TYPE,  2022–2030 (USD MILLION)      452

TABLE 531            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)            453

TABLE 532            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            453

TABLE 533            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,  BY TYPE, 2022–2030 (USD MILLION) 454

TABLE 534            MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,  2022–2030 (USD MILLION)                 454

TABLE 535            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,

2022–2030 (USD MILLION)            455

TABLE 536            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,

2022–2030 (USD MILLION)            456

TABLE 537            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,  BY TYPE, 2022–2030 (USD MILLION)                 456

TABLE 538            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY APPLICATION,

2022–2030 (USD MILLION)            457

TABLE 539            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE,  2022–2030 (USD MILLION)                 457

TABLE 540            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE,  2022–2030 (USD MILLION)            458

TABLE 541            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION,  BY TYPE, 2022–2030 (USD MILLION) 458

TABLE 542            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE,  2022–2030 (USD MILLION)            459

TABLE 543            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)            459

TABLE 544            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION)       460

TABLE 545            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE,  2022–2030 (USD MILLION)                 460

TABLE 546            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE,  BY TYPE, 2022–2030 (USD MILLION) 461

TABLE 547            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)                461

TABLE 548            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION)         462

TABLE 549            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY CANCER TYPE,

2022–2030 (USD MILLION)            462

TABLE 550            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,

BY TYPE,  2022–2030 (USD MILLION)      463

TABLE 551            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES,  BY TYPE, 2022–2030 (USD MILLION) 463

TABLE 552            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY END USER,

2022–2030 (USD MILLION)            464

TABLE 553            GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS,

BY TYPE, 2022–2030 (USD MILLION)         464

TABLE 554            GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2022–2030 (USD MILLION)            465

TABLE 555            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE,  2022–2030 (USD MILLION)            466

TABLE 556            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY,  2022–2030 (USD MILLION)            466

TABLE 557            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING,  BY TYPE, 2022–2030 (USD MILLION)            467

TABLE 558            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION,  2022–2030 (USD MILLION)            467

TABLE 559            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY,  BY TYPE, 2022–2030 (USD MILLION)       468

TABLE 560            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION)            468

TABLE 561            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION)                469

TABLE 562            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)            469

TABLE 563            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION)                 470

TABLE 564            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 470

TABLE 565            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY,  BY TYPE, 2022–2030 (USD MILLION)            471

TABLE 566            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION)         471

TABLE 567            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION)          472

TABLE 568            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE,

2022–2030 (USD MILLION)            472

TABLE 569            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE,  2022–2030 (USD MILLION)            473

TABLE 570            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS,  BY TYPE, 2022–2030 (USD MILLION) 473

TABLE 571            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION)         474

TABLE 572            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER,  2022–2030 (USD MILLION)                 474

TABLE 573            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION)            475

TABLE 574            REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 475

TABLE 575            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS              477

TABLE 576            AI IN ONCOLOGY MARKET: DEGREE OF COMPETITION 480

TABLE 577            AI IN ONCOLOGY MARKET: PLAYER TYPE FOOTPRINT       484

TABLE 578            AI IN ONCOLOGY MARKET: TECHNOLOGY FOOTPRINT       485

TABLE 579            AI IN ONCOLOGY MARKET: DEPLOYMENT MODEL FOOTPRINT      486

TABLE 580            AI IN ONCOLOGY MARKET: REGION FOOTPRINT       487

TABLE 581            AI IN ONCOLOGY MARKET: LIST OF KEY STARTUPS/SMES              490

TABLE 582            AI IN ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES          491

TABLE 583            AI IN ONCOLOGY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–NOVEMBER 2024                 493

TABLE 584            AI IN ONCOLOGY MARKET: DEALS, JANUARY 2021–NOVEMBER 2024    494

TABLE 585            AI IN ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024                 495

TABLE 586            AI IN ONCOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021–

NOVEMBER 2024               495

TABLE 587            NVIDIA CORPORATION: COMPANY OVERVIEW                 496

TABLE 588            NVIDIA CORPORATION: PRODUCTS/SOLUTIONS OFFERED          497

TABLE 589            NVIDIA CORPORATION: DEALS, JANUARY 2021− NOVEMBER 2024 498

TABLE 590            GE HEALTHCARE: COMPANY OVERVIEW                 500

TABLE 591            GE HEALTHCARE: PRODUCTS/SOLUTIONS OFFERED             501

TABLE 592            GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024  502

TABLE 593            GE HEALTHCARE: DEALS, JANUARY 2021− NOVEMBER 2024               502

TABLE 594            SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW          504

TABLE 595            SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS OFFERED          505

TABLE 596            SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024                 506

TABLE 597            SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−NOVEMBER 2024  506

TABLE 598            SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−NOVEMBER 2024               506

TABLE 599            F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW          508

TABLE 600            F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SOLUTIONS OFFERED          509

TABLE 601            F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024                 510

TABLE 602            F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021−NOVEMBER 2024               510

TABLE 603            INSILICO MEDICINE: COMPANY OVERVIEW                 512

TABLE 604            INSILICO MEDICINE: PRODUCTS/SOLUTIONS OFFERED             512

TABLE 605            INSILICO MEDICINE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– NOVEMBER 2024    513

TABLE 606            INSILICO MEDICINE: DEALS, JANUARY 2021–NOVEMBER 2024               514

TABLE 607            INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 519

TABLE 608            CONCERTAI: COMPANY OVERVIEW        521

TABLE 609            CONCERTAI: PRODUCTS/SOLUTIONS OFFERED                 521

TABLE 610            CONCERTAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−

NOVEMBER 2024               522

TABLE 611            CONCERTAI: DEALS, JANUARY 2021−NOVEMBER 2024  522

TABLE 612            MEDTRONIC: COMPANY OVERVIEW       523

TABLE 613            MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED             524

TABLE 614            MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−

NOVEMBER 2024               525

TABLE 615            MEDTRONIC: DEALS, JANUARY 2021−NOVEMBER 2024  525

TABLE 616            ORACLE: COMPANY OVERVIEW                526

TABLE 617            ORACLE: PRODUCTS/SOLUTIONS OFFERED                 527

TABLE 618            ORACLE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024               528

TABLE 619            ORACLE: DEALS, JANUARY 2021−NOVEMBER 2024        528

TABLE 620            KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW          529

TABLE 621            KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS OFFERED          530

TABLE 622            KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−NOVEMBER 2024  531

TABLE 623            PREDICTIVE ONCOLOGY: COMPANY OVERVIEW          532

TABLE 624            PREDICTIVE ONCOLOGY: PRODUCTS/SOLUTIONS OFFERED          533

TABLE 625            PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024                 533

TABLE 626            PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−NOVEMBER 2024  533

TABLE 627            EXSCIENTIA: COMPANY OVERVIEW        534

TABLE 628            EXSCIENTIA: PRODUCTS/SOLUTIONS OFFERED                 535

TABLE 629            EXSCIENTIA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–

NOVEMBER 2024               536

TABLE 630            EXSCIENTIA: DEALS, JANUARY 2021–NOVEMBER 2024        536

TABLE 631            EXSCIENTIA: EXPANSIONS, JANUARY 2021–NOVEMBER 2024               541

TABLE 632            EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 542

TABLE 633            PATHAI, INC.: COMPANY OVERVIEW      543

TABLE 634            PATHAI, INC.: PRODUCTS/SOLUTIONS OFFERED             543

TABLE 635            PATHAI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−

NOVEMBER 2024               544

TABLE 636            PATHAI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024  544

TABLE 637            CUREMETRIX, INC.: COMPANY OVERVIEW                 545

TABLE 638            CUREMETRIX, INC.: PRODUCTS/SOLUTIONS OFFERED             545

TABLE 639            CUREMETRIX, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024               545

TABLE 640            MINDPEAK GMBH: COMPANY OVERVIEW                 546

TABLE 641            MINDPEAK GMBH: PRODUCTS/SOLUTIONS OFFERED             546

TABLE 642            MINDPEAK GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024  547

TABLE 643            MINDPEAK GMBH: DEALS, JANUARY 2021−NOVEMBER 2024  547

TABLE 644            MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024               547

TABLE 645            PAIGE AI, INC.: COMPANY OVERVIEW    548

TABLE 646            PAIGE AI, INC.: PRODUCTS/SOLUTIONS OFFERED             548

TABLE 647            PAIGE AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−

NOVEMBER 2024               549

TABLE 648            PAIGE AI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024  549

TABLE 649            PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024               550

TABLE 650            TEMPUS AI, INC.: COMPANY OVERVIEW                 551

TABLE 651            TEMPUS AI, INC.: PRODUCTS/SOLUTIONS OFFERED             551

TABLE 652            TEMPUS AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–

NOVEMBER 2024               552

TABLE 653            TEMPUS AI, INC.: DEALS, JANUARY 2021–NOVEMBER 2024               553

TABLE 654            TEMPUS AI, INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024               555

TABLE 655            TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024                 556

TABLE 656            IKTOS: COMPANY OVERVIEW    557

TABLE 657            IKTOS: PRODUCTS/SOLUTIONS OFFERED                 557

TABLE 658            IKTOS: DEALS, JANUARY 2021–NOVEMBER 2024                 558

TABLE 659            IKTOS: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024    561

LIST OF FIGURES

FIGURE 1              RESEARCH DESIGN         53

FIGURE 2              BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,

AND REGION     58

FIGURE 3              RESEARCH METHODOLOGY: HYPOTHESIS BUILDING           59

FIGURE 4              SUPPLY-SIDE MARKET ESTIMATION      61

FIGURE 5              AI IN ONCOLOGY MARKET: REVENUE ESTIMATION APPROACH              61

FIGURE 6              BOTTOM-UP APPROACH (2A): END USER SPENDING ON AI IN ONCOLOGY              63

FIGURE 7              BOTTOM-UP APPROACH (2B): END USER SPENDING ON AI IN ONCOLOGY              64

FIGURE 8              CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030)          66

FIGURE 9              CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS                 67

FIGURE 10            TOP-DOWN APPROACH                67

FIGURE 11            DATA TRIANGULATION METHODOLOGY                 68

FIGURE 12            INTEGRATED SUITE/PLATFORM PROVIDERS SEGMENT TO LEAD MARKET  BY 2030  71

FIGURE 13            DIAGNOSIS & EARLY DETECTION SEGMENT TO ACCOUNT FOR LARGEST

SHARE BY 2030   72

FIGURE 14            SOLID TUMORS SEGMENT TO LEAD MARKET BY 2030 72

FIGURE 15            AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL,

2024 VS. 2030 (USD MILLION)    73

FIGURE 16            MACHINE LEARNING SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030     73

FIGURE 17            HEALTHCARE PROVIDERS SEGMENT TO LEAD MARKET BY 2030               74

FIGURE 18            ASIA PACIFIC TO ACHIEVE HIGHEST GROWTH DURING FORECAST PERIOD       75

FIGURE 19            FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET               76

FIGURE 20            NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD        77

FIGURE 21            CLOUD-BASED MODEL AND US ACCOUNTED FOR SIGNIFICANT SHARE IN 2023              77

FIGURE 22            INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD       78

FIGURE 23            GROWTH RATES OF EMERGING MARKETS TO BE HIGHER THAN THOSE OF DEVELOPED MARKETS DURING FORECAST PERIOD         78

FIGURE 24            AI IN ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          79

FIGURE 25            NEW CANCER CASES AND CANCER DEATHS IN US, 2024                 80

FIGURE 26            FUNDING RECEIVED BY AI IN ONCOLOGY COMPANIES IN 2024        82

FIGURE 27            NUMBER OF CANCER PUBLICATIONS OVER TIME (WITH OR WITHOUT

AI AND RADIOMICS)      85

FIGURE 28            DISTRIBUTION OF CANCER CLINICAL TRIALS, BY PHASE            86

FIGURE 29            AI IN ONCOLOGY MARKET: ECOSYSTEM ANALYSIS            89

FIGURE 30            AI IN ONCOLOGY MARKET: VALUE CHAIN ANALYSIS            93

FIGURE 31            PORTER’S FIVE FORCES ANALYSIS OF AI IN ONCOLOGY MARKET     95

FIGURE 32            PATENT PUBLICATION TRENDS IN AI IN ONCOLOGY MARKET, 2015–2024                103

FIGURE 33            JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN ONCOLOGY” PATENTS (JANUARY 2015–SEPTEMBER 2024)             104

FIGURE 34            MAJOR PATENTS IN AI IN ONCOLOGY MARKET (JANUARY 2015–

SEPTEMBER 2024)             105

FIGURE 35            AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023                 110

FIGURE 36            INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS 111

FIGURE 37            KEY BUYING CRITERIA FOR TOP 3 END USERS                 112

FIGURE 38            TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS   113

FIGURE 39            INVESTMENT AND FUNDING SCENARIO IN AI IN ONCOLOGY MARKET     114

FIGURE 40            POTENTIAL OF GENERATIVE AI IN AI IN ONCOLOGY MARKET     115

FIGURE 41            IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS          117

FIGURE 42            NEW CANCER CASES IN US, BY CANCER TYPE, 2024        192

FIGURE 43            PERCENTAGE ESTIMATION OF HEMATOLOGIC MALIGNANCY CASES IN US,

BY TYPE, 2024     199

FIGURE 44            AI IN ONCOLOGY MARKET, BY REGION, 2023 (USD MILLION) 235

FIGURE 45            NORTH AMERICA: AI IN ONCOLOGY MARKET SNAPSHOT          238

FIGURE 46            DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION, 2021 VS. 2022              250

FIGURE 47            DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (MALES)        261

FIGURE 48            DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (FEMALES)   261

FIGURE 49            INCIDENCE OF CANCER IN MALES IN ITALY, BY CANCER TYPE, 2022         315

FIGURE 50            INCIDENCE OF CANCER IN FEMALES IN ITALY, BY CANCER TYPE, 2022  315

FIGURE 51            ASIA PACIFIC: AI IN ONCOLOGY MARKET SNAPSHOT          348

FIGURE 52            REVENUE ANALYSIS OF TOP 5 PLAYERS, 2019–2023 (USD BILLION)        478

FIGURE 53            AI IN ONCOLOGY MARKET SHARE ANALYSIS, 2023        479

FIGURE 54            AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023         482

FIGURE 55            AI IN ONCOLOGY MARKET: COMPANY FOOTPRINT       483

FIGURE 56            AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023                489

FIGURE 57            COMPANY VALUATION OF KEY PLAYERS, 2024                 492

FIGURE 58            EV/EBITDA OF KEY PLAYERS, 2024            492

FIGURE 59            AI IN ONCOLOGY MARKET: BRAND/PRODUCT COMPARISON   493

FIGURE 60            NVIDIA CORPORATION: COMPANY SNAPSHOT (2023)    497

FIGURE 61            GE HEALTHCARE: COMPANY SNAPSHOT (2023)                 501

FIGURE 62            SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023)             505

FIGURE 63            F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)             509

FIGURE 64            MEDTRONIC: COMPANY SNAPSHOT (2023)                 524

FIGURE 65            ORACLE: COMPANY SNAPSHOT (2023)   527

FIGURE 66            KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)             530

FIGURE 67            PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)             532

FIGURE 68            EXSCIENTIA: COMPANY SNAPSHOT        535

MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • ご注文後2営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

割引可能なレポートが多数ございます。価格・サンプルについてはお気軽にご相談ください。

最新調査レポート

• 沈降シリカ市場 – 2030年までの世界予測 2025-03-07
• スマートメーター市場 – 2030年までの世界予測 2025-03-07
• 産業用計測市場 – 2030年までの世界予測 2025-03-06
• 精密ろ過膜市場- 2029年までの世界予測 2025-03-06
• グリーンテクノロジーと持続可能性市場 – 2030年までの世界予測 2025-03-06

MarketsandMarkets  出版レポート一覧